- Overview – the in-vitro to ex-vivo to in-vivo paradigm
- In-vitro - importance of choosing suitable cell lines
- Ex-vivo – adding the complexity of in-vivo background while keeping the simplicity of in-vitro
- In-vivo - all the complexity of ex-vivo plus the “active” components of a real animal
- In-vivo systems are open, “active” systems with multiple layers of complexity
- In-vitro and ex-vivo are mostly “closed” systems, but not absolutely
- What is an “open” system?
- Attempts to isolate open systems
- Layers of complexity of in-vivo systems
- Human cells in nude mice – a mixture of in-vitro and in-vivo
- “Model” small animal systems
- Bbetter model larger animal systems
- Examples of the in-vitro to in-vivo experimental pathway
- Kopelman group – multifunctional NPs for MRI and photodynamic therapy
- Langer group – aptamer-targeted NPs for cancer therapy in-vivo
- Leary group – peptide-guided NPs to human tumors in nude mice magnetic nanoparticles as MRI contrast agents in tissue phantoms
- Kopelman, R., Koo, Y-E, Philbert, M., Moffatc, B.A., Reddy,G.R., McConville, P., Hall, D.E., Chenevert, T.L., Bhojanie, M.S., Buck, S.M., Rehemtulla, A., Ross, B.D. Multifunctional nanoparticle platforms for in vivo MRI enhancement and photodynamic therapy of a rat brain cancer. Journal of Magnetism and Magnetic Materials 293: 404–410, 2005.
- Farokhzad, O.C., Cheng, J., Teply, B.J., Sherifi, I., Jon, S., Kantoff, P.W., Richie, J.P., Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. PNAS 103(16), 6315–6320, 2006
Researchers should cite this work as follows:
James Leary (2007), "BME 695N Lecture 18: Designing nanodelivery systems for in-vivo use," https://nanohub.org/resources/3515.
Biomedical Engineering Building, Room 1083